Cancer-associated fibroblasts and its derived exosomes: a new perspective for reshaping the tumor microenvironment

Molecular Medicine

Review

Manping Ye¹  Zhiwei Tong²  Zihao Ren²  Zhiwei Peng²  Kongwang Hu³ 

[1] Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, 230032, Hefei, Anhui, China;Department of General Surgery, First Affiliated Hospital of Anhui Medical University, 230022, Hefei, Anhui, China;Department of General Surgery, First Affiliated Hospital of Anhui Medical University, 230022, Hefei, Anhui, China;Department of General Surgery, Fuyang Affiliated Hospital of Anhui Medical University, 236000, Fuyang, Anhui, China;

关键词: Cancer-associated fibroblasts;    Exosomes;    Tumor microenvironment;    Diagnosis;    Therapy;   

DOI  :  10.1186/s10020-023-00665-y

 received in 2023-04-07, accepted in 2023-05-14,  发布年份 2023

来源: Springer

【 摘 要 】

Cancer-associated fibroblasts (CAFs) are the most abundant stromal cells within the tumor microenvironment (TME). They extensively communicate with the other cells. Exosome-packed bioactive molecules derived from CAFs can reshape the TME by interacting with other cells and the extracellular matrix, which adds a new perspective for their clinical application in tumor targeted therapy. An in-depth understanding of the biological characteristics of CAF-derived exosomes (CDEs) is critical for depicting the detailed landscape of the TME and developing tailored therapeutic strategies for cancer treatment. In this review, we have summarized the functional roles of CAFs in the TME, particularly focusing on the extensive communication mediated by CDEs that contain biological molecules such as miRNAs, proteins, metabolites, and other components. In addition, we have also highlighted the prospects for diagnostic and therapeutic applications based on CDEs, which could guide the future development of exosome-targeted anti-tumor drugs.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

40517_2023_256_Article_IEq16.gif

Fig. 4

40517_2023_256_Article_IEq13.gif

40517_2023_256_Article_IEq12.gif

40517_2023_256_Article_IEq208.gif

40517_2023_256_Article_IEq5.gif

41116_2023_36_Article_IEq60.gif

41116_2023_36_Article_IEq51.gif

41116_2023_36_Article_IEq43.gif

41116_2023_36_Article_IEq34.gif

41116_2023_36_Article_IEq5.gif